This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
Prescribing Information

A digital infographic of the effect of STEGLATRO (ertugliflozin) on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy1

Reference

  1. Rosenstock, J et al. Diabetes, Obesity and Metabolism. 2018; 20(3):520-52.

Supporting documentation

STEGLATRO® (ertugliflozin) 5 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

STEGLATRO® (ertugliflozin) 15 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-STE-00111 | Date of Preparation: May 2019